|Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|Outline of Final Research Achievements
Six pretherapeutic plasma samples of each three different chemotherapy-sensitive and chemotherapy-resistant ESCC patients were selected for the 3D-GENE microarray analysis . Twenty-eight miRNAs have been reported to be upregulated in plasma of chemotherapy-resistant ESCC patients. We chose miR-193b- 5p, miR-873-3p and miR-23a-5p of them as candidates for therapeutic effect predictive markers in this study.
The levels of miR-193b- 5p, miR-873-3p and miR-23a-5p were examined for 111 plasma samples in ESCC patients who received neoadjuvant chemotherapy with cisplatin/5-FU. MiR-193b-5p and miR-873-3p were significantly highly expressed in plasma of chemotherapy-resistant ESCC patients than those of chemotherapy-sensitive patients (P = 0.044, P = 0.025). Hence, patients with high expression of miR-193b-5p or miR-873-3p in plasma will become to resistant chemotherapy with cisplatin/5-FU as the first line of ESCC in Japan.